Avidity
Edward Kaye is a board member at Avidity. Edward has also served as president of Akcea Therapeutics, chief business officer and senior vice president of Ionis Pharmaceuticals, vice president of international business strategy and operations ofForest Laboratories, and VP of nephrology at Alexion Pharmaceuticals. Edward began their career in 1999 as VP of global pro gram head pediatric and speciality business at Novartis Vaccines and Diagnostics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.